The PBAC has recommended Alyftrek for listing on the PBS, a significant milestone for Australians living with cystic fibrosis (CF).
Alyftrek is a once-daily triple-combination CFTR modulator therapy for people aged 6+ with at least one F508del or another responsive CFTR mutation.
While TGA approval and final processes are still underway, we’re hopeful that the PBS listing will occur in the first quarter of 2026. CFA is working closely with all stakeholders to ensure timely access for the community.
Why this matters: More Australians with CF will have access to life-changing treatment that can improve lung function and quality of life.
Read more about Alyftrek and what this means for the CF community: http://bit.ly/4qkq5ue